Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Cilloni

Showing results (151-160 of 193) with videos related to

Pageof 20
Sort By:
European Journal of Haematology|March 4, 2014
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)Emanuele Angelucci, Valeria Santini, Anna Angela Di Tucci, et al.
Blood|February 15, 2007
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic, Joannah Score, Katherine Waghorn, et al.
Blood|January 6, 2005
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?Michele Malagola, Giovanni Martinelli, Michela Rondoni, et al.
American Journal of Blood Research|July 5, 2012
Quality of life and physicians' perception in myelodysplastic syndromesEsther Natalie Oliva, Carlo Finelli, Valeria Santini, et al.
Blood|July 11, 2009
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)Ilaria Iacobucci, Clelia Tiziana Storlazzi, Daniela Cilloni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet studyDaniela Cilloni, Aline Renneville, Fabienne Hermitte, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase MyelofibrosisFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
Blood|July 20, 2002
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaAgostino Tafuri, Chiara Gregorj, Maria T Petrucci, et al.
Blood Advances|June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with RuxolitinibFrancesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
Cancer|March 30, 2025
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life settingJacopo Nanni, Irene Azzali, Cristina Papayannidis, et al.
Pageof 20

Showing results (151-160 of 193) with videos related to

Sort By:
Pageof 20
European Journal of Haematology|March 4, 2014
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)Emanuele Angelucci, Valeria Santini, Anna Angela Di Tucci, et al.
Blood|February 15, 2007
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaJelena V Jovanovic, Joannah Score, Katherine Waghorn, et al.
Blood|January 6, 2005
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?Michele Malagola, Giovanni Martinelli, Michela Rondoni, et al.
American Journal of Blood Research|July 5, 2012
Quality of life and physicians' perception in myelodysplastic syndromesEsther Natalie Oliva, Carlo Finelli, Valeria Santini, et al.
Blood|July 11, 2009
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)Ilaria Iacobucci, Clelia Tiziana Storlazzi, Daniela Cilloni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet studyDaniela Cilloni, Aline Renneville, Fabienne Hermitte, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase MyelofibrosisFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.
Blood|July 20, 2002
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaAgostino Tafuri, Chiara Gregorj, Maria T Petrucci, et al.
Blood Advances|June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with RuxolitinibFrancesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.
Cancer|March 30, 2025
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life settingJacopo Nanni, Irene Azzali, Cristina Papayannidis, et al.
Pageof 20